Biogen (NASDAQ:BIIB) Releases FY 2026 Earnings Guidance

Biogen (NASDAQ:BIIB) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 14.250-15.250 for the period, compared to the consensus earnings per share estimate of 15.590. The company issued revenue guidance of -, compared to the consensus revenue estimate of $9.5 billion.

Biogen Stock Down 2.6%

Shares of NASDAQ:BIIB opened at $189.28 on Friday. The stock has a 50-day simple moving average of $184.52 and a 200-day simple moving average of $176.06. The stock has a market capitalization of $27.78 billion, a P/E ratio of 20.31, a PEG ratio of 1.63 and a beta of 0.16. Biogen has a 1 year low of $115.25 and a 1 year high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts forecast that Biogen will post 14.91 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BIIB shares. UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and lifted their target price for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. Stifel Nicolaus raised their price objective on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. boosted their price objective on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Rothschild & Co Redburn increased their target price on Biogen from $150.00 to $180.00 and gave the company a “neutral” rating in a research note on Wednesday, April 22nd. Finally, Canaccord Genuity Group raised their target price on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Fourteen investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Biogen currently has an average rating of “Hold” and a consensus target price of $213.12.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.18% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat — Biogen reported better‑than‑expected Q1 revenue and EPS (revenue $2.48B; non‑GAAP EPS $3.57), driven by growth-product sales and strong commercial execution, which is a key reason investors pushed the stock higher after results. Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Growth-product tailwinds — Management highlighted in‑market LEQEMBI and SKYCLARYS sales and a Spinraza high‑dose approval; investors view these as sustainable revenue drivers that underpin the beat and longer‑term upside. Biogen shares rise after Q1 earnings beat, growth-product momentum, and pipeline/M&A updates
• Positive Sentiment: Analyst price‑target lifts — Multiple firms raised targets (RBC to $222, HC Wainwright to $237 and TD Cowen $215) and issued Buy/outperform notes, supporting upside prospects and helping offset guidance worries. RBC raises price target to $222 HC Wainwright raises PT to $237
• Neutral Sentiment: BMO keeps Hold — Some analysts remain cautious on near‑term growth and kept neutral/market‑perform ratings (BMO $196 PT), reflecting debate over how quickly new product momentum will offset costs. Biogen kept at Hold by BMO
• Neutral Sentiment: Mixed analyst views — Street reactions range from cautious to bullish; consensus price‑target dispersion is wide, so expect continued volatility as guidance clarity and M&A detail emerge. Analysts’ Opinions Are Mixed
• Negative Sentiment: Guidance trimmed on acquisition charges — Biogen narrowed FY‑2026 non‑GAAP EPS to $14.25–$15.25, citing acquisition‑related IPR&D and other M&A charges tied to business development (Apellis deal impacts), which trimmed some of the upside from the quarter and prompted concern over near‑term earnings. Biogen cuts annual profit forecast on acquisition-related charges (Reuters)
• Negative Sentiment: One‑time M&A costs weigh on outlook — Coverage notes the EPS trim reflects transaction costs rather than core operating weakness, but the cut still creates near‑term downside risk until the strategic rationale and integration benefits are clearer. Biogen beats Q1 but cuts 2026 EPS view (Zacks)

Institutional Trading of Biogen

A number of hedge funds and other institutional investors have recently made changes to their positions in BIIB. WFA of San Diego LLC bought a new position in Biogen during the 2nd quarter valued at $32,000. Strive Financial Group LLC bought a new stake in shares of Biogen in the 4th quarter worth about $35,000. DV Equities LLC bought a new stake in shares of Biogen in the 4th quarter worth about $36,000. Meeder Asset Management Inc. raised its stake in shares of Biogen by 323.5% in the 4th quarter. Meeder Asset Management Inc. now owns 216 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 165 shares in the last quarter. Finally, Summit Securities Group LLC lifted its position in shares of Biogen by 346.9% during the fourth quarter. Summit Securities Group LLC now owns 219 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 170 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.